Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
European Association for the Study of Diabetes to hold a virtual annual meeting » 05:55
09/25/20
09/25
05:55
09/25/20
05:55
ABT

Abbott

$100.91 /

-1.81 (-1.76%)

, AMRN

Amarin

$3.64 /

-0.035 (-0.95%)

, AMYT

Amryt Pharma

$11.57 /

-0.48 (-3.98%)

, AZN

AstraZeneca

$54.18 /

-1.495 (-2.69%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, DXCM

DexCom

$382.64 /

-2.39 (-0.62%)

, GILD

Gilead

$62.26 /

-0.85 (-1.35%)

, LLY

Eli Lilly

$148.89 /

-1 (-0.67%)

, MDT

Medtronic

$101.30 /

-0.52 (-0.51%)

, MRK

Merck

$83.17 /

+0.54 (+0.65%)

, NVO

Novo Nordisk

$68.25 /

-1.195 (-1.72%)

, NVS

Novartis

$86.30 /

-1.15 (-1.32%)

, PODD

Insulet

$216.60 /

-11.07 (-4.86%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SNY

Sanofi

$50.75 /

+0.15 (+0.30%)

, TNDM

TNDM

/

+

, VTVT

vTv Therapeutics

$1.73 /

-0.09 (-4.95%)

56th Virtual Annual…

56th Virtual Annual Meeting of EASD will be held on September 21-25. Webcast Link

ShowHide Related Items >><<
VTVT vTv Therapeutics
$1.73 /

-0.09 (-4.95%)

TNDM TNDM
/

+

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PODD Insulet
$216.60 /

-11.07 (-4.86%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMYT Amryt Pharma
$11.57 /

-0.48 (-3.98%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

09/11/20 Wolfe Research
Abbott initiated with an Outperform at Wolfe Research
08/31/20 Credit Suisse
Abbott price target raised to $136 from $109 at Credit Suisse
08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
08/28/20 Piper Sandler
COVID-19 test provider selloff on Abbott approval overdone, says Piper
AMRN Amarin
$3.64 /

-0.035 (-0.95%)

09/08/20 Cantor Fitzgerald
Amarin price target lowered to $15 from $35 at Cantor Fitzgerald
09/04/20 Northland
Amarin generic competitors to be constrained by supply chains, says Northland
09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
09/03/20 Stifel
Amarin price target lowered to $5 from $8 at Stifel
AMYT Amryt Pharma
$11.57 /

-0.48 (-3.98%)

07/20/20
Fly Intel: Top five analyst initiations
07/20/20 Canaccord
Amryt Pharma initiated with a Buy at Canaccord
07/09/20
Fly Intel: Top five analyst initiations
07/08/20 Cantor Fitzgerald
Cantor Fitzgerald starts Amryt at Overweight, sees number of catalysts upcoming
AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

09/23/20 Oddo BHF
AstraZeneca upgraded to Buy from Reduce at Oddo BHF
09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

09/14/20 Morgan Stanley
Bayer price target lowered to EUR 82 from EUR 83 at Morgan Stanley
09/10/20
Fly Intel: Top five analyst initiations
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
09/09/20 BMO Capital
Bayer initiated with a Market Perform at BMO Capital
DXCM DexCom
$382.64 /

-2.39 (-0.62%)

08/11/20 Piper Sandler
Medtronic acquisition of Companion 'a smart decision,' says Piper Sandler
07/29/20 SVB Leerink
DexCom price target raised to $485 from $465 at SVB Leerink
07/29/20 Guggenheim
DexCom price target raised to $500 from $395 at Guggenheim
07/29/20 Canaccord
DexCom price target raised to $500 from $435 at Canaccord
GILD Gilead
$62.26 /

-0.85 (-1.35%)

09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
09/20/20 Citi
Immunomedics presents at ESMO, readouts exceeded expectations, says Citi
09/18/20 RBC Capital
Gilead price target raised to $86 from $82 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
LLY Eli Lilly
$148.89 /

-1 (-0.67%)

09/21/20 Morgan Stanley
Eli Lilly's Verzenio 'clear winner' over Pfizer's Ibrance, says Morgan Stanley
09/16/20 Canaccord
Eli Lilly COVID-19 data bodes well for Regeneron, says Canaccord
09/16/20 Goldman Sachs
Eli Lilly COVID-19 antibody data 'encouraging,' says Goldman Sachs
09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
MDT Medtronic
$101.30 /

-0.52 (-0.51%)

09/11/20 Wolfe Research
Medtronic initiated with a Peer Perform at Wolfe Research
08/26/20 Raymond James
Medtronic price target raised to $115 from $107 at Raymond James
08/26/20 BTIG
Medtronic price target raised to $111 from $102 at BTIG
08/26/20 Citi
Medtronic price target raised to $120 from $108 at Citi
MRK Merck
$83.17 /

+0.54 (+0.65%)

09/24/20 Roth Capital
Merck data suggests 'another shot on goal' for Jounce, says Roth Capital
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
NVS Novartis
$86.30 /

-1.15 (-1.32%)

09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
PODD Insulet
$216.60 /

-11.07 (-4.86%)

08/07/20 Stephens
Insulet price target raised to $230 from $165 at Stephens
08/07/20 Citi
Insulet price target raised to $255 from $200 at Citi
08/06/20 Piper Sandler
Insulet price target raised to $260 from $235 at Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
SNY Sanofi
$50.75 /

+0.15 (+0.30%)

09/14/20 Roth Capital
Immunic has 'significant' opportunity in RRMS, says Roth Capital
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/19/20 Stifel
Principia Biopharma downgraded to Hold from Buy at Stifel
TNDM TNDM
/

+

08/20/20
Fly Intel: Top five analyst initiationsNewPage
08/20/20 Wells Fargo
Tandem Diabetes initiated with an Overweight at Wells Fargo
07/31/20 Craig-Hallum
Tandem Diabetes price target raised to $140 from $102 at Craig-Hallum
VTVT vTv Therapeutics
$1.73 /

-0.09 (-4.95%)

02/10/20 H.C. Wainwright
vTv Therapeutics price target raised to $6 from $5 at H.C. Wainwright
TNDM TNDM
/

+

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PODD Insulet
$216.60 /

-11.07 (-4.86%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

  • 13
    May
SNY Sanofi
$50.75 /

+0.15 (+0.30%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

TNDM TNDM
/

+

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

PODD Insulet
$216.60 /

-11.07 (-4.86%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

Thursday
Hot Stocks
Becton Dickinson pays $60M in settlement over Bard's mesh devices » 12:30
09/24/20
09/24
12:30
09/24/20
12:30
BDX

Becton Dickinson

$220.90 /

-4.79 (-2.12%)

South Dakota Attorney…

South Dakota Attorney General Jason Ravnsborg announced a settlement by 48 states and the District of Columbia with C.R. Bard and its parent company Becton Dickinson (BDX) requiring payment of $60M for the "deceptive marketing of transvaginal surgical mesh devices." The attorneys general allege that C.R. Bard "misrepresented or failed to adequately disclose serious and life-altering risks of surgical mesh devices, such as chronic pain, scarring and shrinking of bodily tissue, painful sexual relations, and recurring infections, among other complications." C.R. Bard and Becton Dickinson and agreed to pay $60M to the 48 participating states and the District of Columbia. "Although C.R. Bard stopped selling transvaginal mesh, the settlement provides injunctive relief, requiring both C.R. Bard and Becton, Dickinson and Company to adhere to certain injunctive terms if they reenter the transvaginal mesh market," Jason Ravnsborg said in a statement. Reference Link

ShowHide Related Items >><<
BDX Becton Dickinson
$220.90 /

-4.79 (-2.12%)

BDX Becton Dickinson
$220.90 /

-4.79 (-2.12%)

08/27/20 Goldman Sachs
Abbott test's sensitivity, low price 'positive surprises,' says Goldman Sachs
08/27/20 Wells Fargo
Abbott not focused on bringing Covid-19 test to home, says Wells Fargo
08/27/20 Morgan Stanley
Abbott 'may change the game' in COVID testing with BinaxNOW, says Morgan Stanley
08/07/20 Raymond James
Becton Dickinson price target raised to $285 from $265 at Raymond James
BDX Becton Dickinson
$220.90 /

-4.79 (-2.12%)

  • 21
    May
BDX Becton Dickinson
$220.90 /

-4.79 (-2.12%)

BDX Becton Dickinson
$220.90 /

-4.79 (-2.12%)

Conference/Events
European Association for the Study of Diabetes to hold a virtual annual meeting » 04:55
09/24/20
09/24
04:55
09/24/20
04:55
ABT

Abbott

$102.72 /

-2.07 (-1.98%)

, AMRN

Amarin

$3.68 /

-0.165 (-4.30%)

, AMYT

Amryt Pharma

$12.05 /

+ (+0.00%)

, AZN

AstraZeneca

$55.68 /

+0.235 (+0.42%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, DXCM

DexCom

$386.13 /

-12 (-3.01%)

, GILD

Gilead

$63.10 /

-0.29 (-0.46%)

, LLY

Eli Lilly

$149.89 /

-0.04 (-0.03%)

, MDT

Medtronic

$102.97 /

-1.36 (-1.30%)

, MRK

Merck

$82.63 /

-0.3 (-0.36%)

, NVO

Novo Nordisk

$69.45 /

+0.36 (+0.52%)

, NVS

Novartis

$87.45 /

-1.42 (-1.60%)

, PODD

Insulet

$227.64 /

-2.48 (-1.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SNY

Sanofi

$50.60 /

+0.7 (+1.40%)

, TNDM

TNDM

/

+

, VTVT

vTv Therapeutics

$1.82 /

-0.06 (-3.19%)

56th Virtual Annual…

56th Virtual Annual Meeting of EASD will be held on September 21-25. Webcast Link

ShowHide Related Items >><<
VTVT vTv Therapeutics
$1.82 /

-0.06 (-3.19%)

TNDM TNDM
/

+

SNY Sanofi
$50.60 /

+0.7 (+1.40%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PODD Insulet
$227.64 /

-2.48 (-1.08%)

NVS Novartis
$87.45 /

-1.42 (-1.60%)

NVO Novo Nordisk
$69.45 /

+0.36 (+0.52%)

MRK Merck
$82.63 /

-0.3 (-0.36%)

MDT Medtronic
$102.97 /

-1.36 (-1.30%)

LLY Eli Lilly
$149.89 /

-0.04 (-0.03%)

GILD Gilead
$63.10 /

-0.29 (-0.46%)

DXCM DexCom
$386.13 /

-12 (-3.01%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.68 /

+0.235 (+0.42%)

AMYT Amryt Pharma
$12.05 /

+ (+0.00%)

AMRN Amarin
$3.68 /

-0.165 (-4.30%)

ABT Abbott
$102.72 /

-2.07 (-1.98%)

ABT Abbott
$102.72 /

-2.07 (-1.98%)

09/11/20 Wolfe Research
Abbott initiated with an Outperform at Wolfe Research
08/31/20 Credit Suisse
Abbott price target raised to $136 from $109 at Credit Suisse
08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
08/28/20 Piper Sandler
COVID-19 test provider selloff on Abbott approval overdone, says Piper
AMRN Amarin
$3.68 /

-0.165 (-4.30%)

09/08/20 Cantor Fitzgerald
Amarin price target lowered to $15 from $35 at Cantor Fitzgerald
09/04/20 Northland
Amarin generic competitors to be constrained by supply chains, says Northland
09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
09/03/20 Stifel
Amarin price target lowered to $5 from $8 at Stifel
AMYT Amryt Pharma
$12.05 /

+ (+0.00%)

07/20/20
Fly Intel: Top five analyst initiations
07/20/20 Canaccord
Amryt Pharma initiated with a Buy at Canaccord
07/09/20
Fly Intel: Top five analyst initiations
07/08/20 Cantor Fitzgerald
Cantor Fitzgerald starts Amryt at Overweight, sees number of catalysts upcoming
AZN AstraZeneca
$55.68 /

+0.235 (+0.42%)

09/23/20 Oddo BHF
AstraZeneca upgraded to Buy from Reduce at Oddo BHF
09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

09/14/20 Morgan Stanley
Bayer price target lowered to EUR 82 from EUR 83 at Morgan Stanley
09/10/20
Fly Intel: Top five analyst initiations
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
09/09/20 BMO Capital
Bayer initiated with a Market Perform at BMO Capital
DXCM DexCom
$386.13 /

-12 (-3.01%)

08/11/20 Piper Sandler
Medtronic acquisition of Companion 'a smart decision,' says Piper Sandler
07/29/20 SVB Leerink
DexCom price target raised to $485 from $465 at SVB Leerink
07/29/20 Guggenheim
DexCom price target raised to $500 from $395 at Guggenheim
07/29/20 Canaccord
DexCom price target raised to $500 from $435 at Canaccord
GILD Gilead
$63.10 /

-0.29 (-0.46%)

09/20/20 Citi
Immunomedics presents at ESMO, readouts exceeded expectations, says Citi
09/18/20 RBC Capital
Gilead price target raised to $86 from $82 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/15/20 Maxim
Gilead upgraded to Buy at Maxim following Immunomedics deal
LLY Eli Lilly
$149.89 /

-0.04 (-0.03%)

09/21/20 Morgan Stanley
Eli Lilly's Verzenio 'clear winner' over Pfizer's Ibrance, says Morgan Stanley
09/16/20 Canaccord
Eli Lilly COVID-19 data bodes well for Regeneron, says Canaccord
09/16/20 Goldman Sachs
Eli Lilly COVID-19 antibody data 'encouraging,' says Goldman Sachs
09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
MDT Medtronic
$102.97 /

-1.36 (-1.30%)

09/11/20 Wolfe Research
Medtronic initiated with a Peer Perform at Wolfe Research
08/26/20 Raymond James
Medtronic price target raised to $115 from $107 at Raymond James
08/26/20 BTIG
Medtronic price target raised to $111 from $102 at BTIG
08/26/20 Citi
Medtronic price target raised to $120 from $108 at Citi
MRK Merck
$82.63 /

-0.3 (-0.36%)

09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
NVO Novo Nordisk
$69.45 /

+0.36 (+0.52%)

08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
NVS Novartis
$87.45 /

-1.42 (-1.60%)

09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
09/10/20 UBS
Novartis upgraded to Buy from Neutral at UBS
PODD Insulet
$227.64 /

-2.48 (-1.08%)

08/07/20 Stephens
Insulet price target raised to $230 from $165 at Stephens
08/07/20 Citi
Insulet price target raised to $255 from $200 at Citi
08/06/20 Piper Sandler
Insulet price target raised to $260 from $235 at Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
SNY Sanofi
$50.60 /

+0.7 (+1.40%)

09/14/20 Roth Capital
Immunic has 'significant' opportunity in RRMS, says Roth Capital
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/19/20 Stifel
Principia Biopharma downgraded to Hold from Buy at Stifel
TNDM TNDM
/

+

08/20/20
Fly Intel: Top five analyst initiationsNewPage
08/20/20 Wells Fargo
Tandem Diabetes initiated with an Overweight at Wells Fargo
07/31/20 Craig-Hallum
Tandem Diabetes price target raised to $140 from $102 at Craig-Hallum
VTVT vTv Therapeutics
$1.82 /

-0.06 (-3.19%)

02/10/20 H.C. Wainwright
vTv Therapeutics price target raised to $6 from $5 at H.C. Wainwright
TNDM TNDM
/

+

SNY Sanofi
$50.60 /

+0.7 (+1.40%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PODD Insulet
$227.64 /

-2.48 (-1.08%)

NVS Novartis
$87.45 /

-1.42 (-1.60%)

NVO Novo Nordisk
$69.45 /

+0.36 (+0.52%)

MRK Merck
$82.63 /

-0.3 (-0.36%)

MDT Medtronic
$102.97 /

-1.36 (-1.30%)

LLY Eli Lilly
$149.89 /

-0.04 (-0.03%)

GILD Gilead
$63.10 /

-0.29 (-0.46%)

DXCM DexCom
$386.13 /

-12 (-3.01%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.68 /

+0.235 (+0.42%)

AMRN Amarin
$3.68 /

-0.165 (-4.30%)

ABT Abbott
$102.72 /

-2.07 (-1.98%)

  • 13
    May
SNY Sanofi
$50.60 /

+0.7 (+1.40%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$87.45 /

-1.42 (-1.60%)

MRK Merck
$82.63 /

-0.3 (-0.36%)

MDT Medtronic
$102.97 /

-1.36 (-1.30%)

LLY Eli Lilly
$149.89 /

-0.04 (-0.03%)

GILD Gilead
$63.10 /

-0.29 (-0.46%)

DXCM DexCom
$386.13 /

-12 (-3.01%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.68 /

+0.235 (+0.42%)

AMRN Amarin
$3.68 /

-0.165 (-4.30%)

ABT Abbott
$102.72 /

-2.07 (-1.98%)

TNDM TNDM
/

+

SNY Sanofi
$50.60 /

+0.7 (+1.40%)

PODD Insulet
$227.64 /

-2.48 (-1.08%)

NVS Novartis
$87.45 /

-1.42 (-1.60%)

NVO Novo Nordisk
$69.45 /

+0.36 (+0.52%)

MRK Merck
$82.63 /

-0.3 (-0.36%)

MDT Medtronic
$102.97 /

-1.36 (-1.30%)

LLY Eli Lilly
$149.89 /

-0.04 (-0.03%)

GILD Gilead
$63.10 /

-0.29 (-0.46%)

DXCM DexCom
$386.13 /

-12 (-3.01%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.68 /

+0.235 (+0.42%)

AMRN Amarin
$3.68 /

-0.165 (-4.30%)

ABT Abbott
$102.72 /

-2.07 (-1.98%)

SNY Sanofi
$50.60 /

+0.7 (+1.40%)

NVO Novo Nordisk
$69.45 /

+0.36 (+0.52%)

MRK Merck
$82.63 /

-0.3 (-0.36%)

MDT Medtronic
$102.97 /

-1.36 (-1.30%)

LLY Eli Lilly
$149.89 /

-0.04 (-0.03%)

GILD Gilead
$63.10 /

-0.29 (-0.46%)

AZN AstraZeneca
$55.68 /

+0.235 (+0.42%)

AMRN Amarin
$3.68 /

-0.165 (-4.30%)

ABT Abbott
$102.72 /

-2.07 (-1.98%)

Wednesday
On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:44
09/23/20
09/23
16:44
09/23/20
16:44
NKE

Nike

$127.03 /

+10.08 (+8.62%)

, TSLA

Tesla

$380.48 /

-43.205 (-10.20%)

, JNJ

Johnson & Johnson

$144.40 /

+0.22 (+0.15%)

, WDC

Western Digital

$38.91 /

+2.43 (+6.66%)

, JPM

JPMorgan

$92.74 /

-1.54 (-1.63%)

, DAL

Delta Air Lines

$29.56 /

-0.65 (-2.15%)

, TWTR

Twitter

$45.33 /

+2.6 (+6.08%)

, ACIU

AC Immune

$4.94 /

-3.775 (-43.34%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RGNX

Regenxbio

$28.59 /

-0.28 (-0.97%)

, NVS

Novartis

$87.45 /

-1.42 (-1.60%)

U.S. equity futures were…

ShowHide Related Items >><<
WDC Western Digital
$38.91 /

+2.43 (+6.66%)

TWTR Twitter
$45.33 /

+2.6 (+6.08%)

TSLA Tesla
$380.48 /

-43.205 (-10.20%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.59 /

-0.28 (-0.97%)

NVS Novartis
$87.45 /

-1.42 (-1.60%)

NKE Nike
$127.03 /

+10.08 (+8.62%)

JPM JPMorgan
$92.74 /

-1.54 (-1.63%)

JNJ Johnson & Johnson
$144.40 /

+0.22 (+0.15%)

DAL Delta Air Lines
$29.56 /

-0.65 (-2.15%)

ACIU AC Immune
$4.94 /

-3.775 (-43.34%)

NKE Nike
$127.03 /

+10.08 (+8.62%)

09/23/20
Fly Intel: Top five analyst upgrades
09/23/20 Needham
Nike price target raised to $149 from $132 at Needham
09/23/20 Guggenheim
Nike price target raised to $165 from $150 at Guggenheim
09/23/20 JPMorgan
Nike price target raised to $140 from $136 at JPMorgan
TSLA Tesla
$380.48 /

-43.205 (-10.20%)

09/24/20 Wedbush
Wedbush downgrades Nikola to sell on 'dark cloud,' Tesla innovations
09/23/20 BMO Capital
BMO thinks Tesla project rights not related to Lithium Americas
09/23/20 Raymond James
Market overreacting to Musk's lithium comments, says Raymond James
JNJ Johnson & Johnson
$144.40 /

+0.22 (+0.15%)

09/01/20 Morgan Stanley
Catalent has potential upside from COVID vaccine, says Morgan Stanley
08/25/20 H.C. Wainwright
Momenta downgraded to Neutral from Buy at H.C. Wainwright
08/24/20 Raymond James
Momenta initiated with a Market Perform at Raymond James
08/24/20 Raymond James
Argenx initiated with an Outperform at Raymond James
WDC Western Digital
$38.91 /

+2.43 (+6.66%)

09/23/20 Cleveland Research
Western Digital upgraded at Cleveland Research on improving demand outlooks
09/23/20 Cleveland Research
Western Digital upgraded to Neutral from Underperform at Cleveland Research
09/23/20 Craig-Hallum
Western Digital upgraded to Buy at Craig-Hallum
09/23/20 Benchmark
Western Digital reorganization could be precursor to spinoff, says Benchmark
JPM JPMorgan
$92.74 /

-1.54 (-1.63%)

09/21/20 Wells Fargo
Money laundering headlines creating extra headline risk for banks, says Wells
09/17/20 RBC Capital
JPMorgan price target raised to $110 from $99 at RBC Capital
09/03/20 Deutsche Bank
JPMorgan upgraded to Buy from Hold at Deutsche Bank
07/24/20
Fly Intel: Top five analyst upgrades
DAL Delta Air Lines
$29.56 /

-0.65 (-2.15%)

09/18/20 Barclays
Delta Air Lines price target raised to $30 from $26 at Barclays
09/15/20 Seaport Global
Delta Air Lines initiated with a Buy at Seaport Global
09/08/20 Morgan Stanley
Delta Air Lines initiated with an Overweight at Morgan Stanley
09/02/20
Fly Intel: Top five analyst downgrades
TWTR Twitter
$45.33 /

+2.6 (+6.08%)

09/24/20 Mizuho
Twitter price target raised to $40 from $33 at Mizuho
09/23/20 Pivotal Research
Twitter upgraded to Buy from Hold at Pivotal Research
09/15/20
Fly Intel: Top five analyst initiations
ACIU AC Immune
$4.94 /

-3.775 (-43.34%)

08/21/20 SVB Leerink
AC Immune upcoming readout risk-reward skews positive, says SVB Leerink
12/10/19 H.C. Wainwright
AC Immune price target raised to $11 from $8 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
RGNX Regenxbio
$28.59 /

-0.28 (-0.97%)

09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/25/20 BofA
Regenxbio reinstated with a Buy at BofA
NVS Novartis
$87.45 /

-1.42 (-1.60%)

09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
WDC Western Digital
$38.91 /

+2.43 (+6.66%)

TWTR Twitter
$45.33 /

+2.6 (+6.08%)

TSLA Tesla
$380.48 /

-43.205 (-10.20%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.59 /

-0.28 (-0.97%)

NVS Novartis
$87.45 /

-1.42 (-1.60%)

NKE Nike
$127.03 /

+10.08 (+8.62%)

JPM JPMorgan
$92.74 /

-1.54 (-1.63%)

JNJ Johnson & Johnson
$144.40 /

+0.22 (+0.15%)

DAL Delta Air Lines
$29.56 /

-0.65 (-2.15%)

ACIU AC Immune
$4.94 /

-3.775 (-43.34%)

  • 14
    Feb
WDC Western Digital
$38.91 /

+2.43 (+6.66%)

TWTR Twitter
$45.33 /

+2.6 (+6.08%)

TSLA Tesla
$380.48 /

-43.205 (-10.20%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$87.45 /

-1.42 (-1.60%)

NKE Nike
$127.03 /

+10.08 (+8.62%)

JPM JPMorgan
$92.74 /

-1.54 (-1.63%)

JNJ Johnson & Johnson
$144.40 /

+0.22 (+0.15%)

DAL Delta Air Lines
$29.56 /

-0.65 (-2.15%)

WDC Western Digital
$38.91 /

+2.43 (+6.66%)

TWTR Twitter
$45.33 /

+2.6 (+6.08%)

TSLA Tesla
$380.48 /

-43.205 (-10.20%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NKE Nike
$127.03 /

+10.08 (+8.62%)

JPM JPMorgan
$92.74 /

-1.54 (-1.63%)

JNJ Johnson & Johnson
$144.40 /

+0.22 (+0.15%)

DAL Delta Air Lines
$29.56 /

-0.65 (-2.15%)

ACIU AC Immune
$4.94 /

-3.775 (-43.34%)

WDC Western Digital
$38.91 /

+2.43 (+6.66%)

TWTR Twitter
$45.33 /

+2.6 (+6.08%)

TSLA Tesla
$380.48 /

-43.205 (-10.20%)

NKE Nike
$127.03 /

+10.08 (+8.62%)

JPM JPMorgan
$92.74 /

-1.54 (-1.63%)

JNJ Johnson & Johnson
$144.40 /

+0.22 (+0.15%)

DAL Delta Air Lines
$29.56 /

-0.65 (-2.15%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:45
09/23/20
09/23
12:45
09/23/20
12:45
NKE

Nike

$128.55 /

+11.6 (+9.92%)

, TSLA

Tesla

$387.76 /

-35.925 (-8.48%)

, JNJ

Johnson & Johnson

$146.13 /

+1.95 (+1.35%)

, WDC

Western Digital

$39.63 /

+3.145 (+8.62%)

, TWTR

Twitter

$46.38 /

+3.65 (+8.54%)

, JKS

JinkoSolar

$33.05 /

+5.36 (+19.36%)

, ACIU

AC Immune

$4.96 /

-3.75 (-43.05%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RGNX

Regenxbio

$28.27 /

-0.6 (-2.08%)

, NVS

Novartis

$88.01 /

-0.86 (-0.97%)

U.S. equity futures were…

ShowHide Related Items >><<
WDC Western Digital
$39.63 /

+3.145 (+8.62%)

TWTR Twitter
$46.38 /

+3.65 (+8.54%)

TSLA Tesla
$387.76 /

-35.925 (-8.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.27 /

-0.6 (-2.08%)

NVS Novartis
$88.01 /

-0.86 (-0.97%)

NKE Nike
$128.55 /

+11.6 (+9.92%)

JNJ Johnson & Johnson
$146.13 /

+1.95 (+1.35%)

JKS JinkoSolar
$33.05 /

+5.36 (+19.36%)

ACIU AC Immune
$4.96 /

-3.75 (-43.05%)

NKE Nike
$128.55 /

+11.6 (+9.92%)

09/23/20
Fly Intel: Top five analyst upgrades
09/23/20 Needham
Nike price target raised to $149 from $132 at Needham
09/23/20 Guggenheim
Nike price target raised to $165 from $150 at Guggenheim
09/23/20 JPMorgan
Nike price target raised to $140 from $136 at JPMorgan
TSLA Tesla
$387.76 /

-35.925 (-8.48%)

09/24/20 Wedbush
Wedbush downgrades Nikola to sell on 'dark cloud,' Tesla innovations
09/23/20 BMO Capital
BMO thinks Tesla project rights not related to Lithium Americas
09/23/20 Raymond James
Market overreacting to Musk's lithium comments, says Raymond James
JNJ Johnson & Johnson
$146.13 /

+1.95 (+1.35%)

09/01/20 Morgan Stanley
Catalent has potential upside from COVID vaccine, says Morgan Stanley
08/25/20 H.C. Wainwright
Momenta downgraded to Neutral from Buy at H.C. Wainwright
08/24/20 Raymond James
Momenta initiated with a Market Perform at Raymond James
08/24/20 Raymond James
Argenx initiated with an Outperform at Raymond James
WDC Western Digital
$39.63 /

+3.145 (+8.62%)

09/23/20 Cleveland Research
Western Digital upgraded at Cleveland Research on improving demand outlooks
09/23/20 Cleveland Research
Western Digital upgraded to Neutral from Underperform at Cleveland Research
09/23/20 Craig-Hallum
Western Digital upgraded to Buy at Craig-Hallum
09/23/20 Benchmark
Western Digital reorganization could be precursor to spinoff, says Benchmark
TWTR Twitter
$46.38 /

+3.65 (+8.54%)

09/24/20 Mizuho
Twitter price target raised to $40 from $33 at Mizuho
09/23/20 Pivotal Research
Twitter upgraded to Buy from Hold at Pivotal Research
09/15/20
Fly Intel: Top five analyst initiations
JKS JinkoSolar
$33.05 /

+5.36 (+19.36%)

09/24/20 Credit Suisse
JinkoSolar upgraded to Outperform from Neutral at Credit Suisse
09/21/20 Roth Capital
JinkoSolar price target raised to $29 from $22 at Roth Capital
07/20/20 Roth Capital
Roth boosts Daqo target to $120 after polysilicon facility explosion reports
06/15/20 GLJ Research
Solar space earnings likely cut through remainder of 2020, says GLJ Research
ACIU AC Immune
$4.96 /

-3.75 (-43.05%)

08/21/20 SVB Leerink
AC Immune upcoming readout risk-reward skews positive, says SVB Leerink
12/10/19 H.C. Wainwright
AC Immune price target raised to $11 from $8 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
RGNX Regenxbio
$28.27 /

-0.6 (-2.08%)

09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/25/20 BofA
Regenxbio reinstated with a Buy at BofA
NVS Novartis
$88.01 /

-0.86 (-0.97%)

09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
WDC Western Digital
$39.63 /

+3.145 (+8.62%)

TWTR Twitter
$46.38 /

+3.65 (+8.54%)

TSLA Tesla
$387.76 /

-35.925 (-8.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.27 /

-0.6 (-2.08%)

NVS Novartis
$88.01 /

-0.86 (-0.97%)

NKE Nike
$128.55 /

+11.6 (+9.92%)

JNJ Johnson & Johnson
$146.13 /

+1.95 (+1.35%)

JKS JinkoSolar
$33.05 /

+5.36 (+19.36%)

ACIU AC Immune
$4.96 /

-3.75 (-43.05%)

  • 14
    Feb
WDC Western Digital
$39.63 /

+3.145 (+8.62%)

TWTR Twitter
$46.38 /

+3.65 (+8.54%)

TSLA Tesla
$387.76 /

-35.925 (-8.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$88.01 /

-0.86 (-0.97%)

NKE Nike
$128.55 /

+11.6 (+9.92%)

JNJ Johnson & Johnson
$146.13 /

+1.95 (+1.35%)

WDC Western Digital
$39.63 /

+3.145 (+8.62%)

TWTR Twitter
$46.38 /

+3.65 (+8.54%)

TSLA Tesla
$387.76 /

-35.925 (-8.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NKE Nike
$128.55 /

+11.6 (+9.92%)

JNJ Johnson & Johnson
$146.13 /

+1.95 (+1.35%)

JKS JinkoSolar
$33.05 /

+5.36 (+19.36%)

ACIU AC Immune
$4.96 /

-3.75 (-43.05%)

WDC Western Digital
$39.63 /

+3.145 (+8.62%)

TWTR Twitter
$46.38 /

+3.65 (+8.54%)

TSLA Tesla
$387.76 /

-35.925 (-8.48%)

NKE Nike
$128.55 /

+11.6 (+9.92%)

JNJ Johnson & Johnson
$146.13 /

+1.95 (+1.35%)

JKS JinkoSolar
$33.05 /

+5.36 (+19.36%)

On The Fly
Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock » 12:10
09/23/20
09/23
12:10
09/23/20
12:10
NVS

Novartis

$88.10 /

-0.77 (-0.87%)

, RGNX

Regenxbio

$28.28 /

-0.59 (-2.04%)

, IONS

Ionis Pharmaceuticals

$50.11 /

-0.63 (-1.24%)

, BIIB

Biogen

$275.85 /

+3.07 (+1.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PTCT

PTC Therapeutics

$46.18 /

+0.06 (+0.13%)

Shares of Regenxbio…

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.28 /

-0.59 (-2.04%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
09/10/20 UBS
Novartis upgraded to Buy from Neutral at UBS
RGNX Regenxbio
$28.28 /

-0.59 (-2.04%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/25/20 BofA
Regenxbio reinstated with a Buy at BofA
05/12/20 RBC Capital
Regenxbio initiated with a Sector Perform at RBC Capital
IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

09/22/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target raised to $59 from $56 at Cantor Fitzgerald
09/14/20 JPMorgan
Ionis Pharmaceuticals resumed with a Neutral at JPMorgan
BIIB Biogen
$275.85 /

+3.07 (+1.13%)

09/18/20 RBC Capital
Biogen price target lowered to $277 from $284 at RBC Capital
09/17/20 Morgan Stanley
Court ruling eliminates hurdle for Tecfidera generics, says Morgan Stanley
09/16/20 Raymond James
Mylan exclusivity on Tecfidera generic abruptly ending, says Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

08/24/20 Raymond James
PTC Therapeutics initiated with an Outperform at Raymond James
08/11/20 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $85 at Cantor Fitzgerald
07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.28 /

-0.59 (-2.04%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

Hot Stocks
Becton Dickinson submits PMA supplement to FDA for BD Onclarity HPV Assay » 09:57
09/23/20
09/23
09:57
09/23/20
09:57
BDX

Becton Dickinson

$227.15 /

+3.3 (+1.47%)

Becton Dickinson…

Becton Dickinson announced that it has submitted a pre-market approval, or PMA, supplement to the FDA for the use of the ThinPrep Pap Test PreservCyt Solution vial as an approved sample type for its BD Onclarity HPV Assay. The PMA supplement would expand the sample claims that can be used in addition to the BD SurePath vial for the detection of human papillomavirus, or HPV, using the BD Onclarity HPV Assay. The submission includes performance data for the BD Viper LT and the BD COR systems. An additional supplement was submitted in January to seek approval for the BD Onclarity HPV assay on the BD COR system and the BD SurePath Liquid Based Cytology vial.

ShowHide Related Items >><<
BDX Becton Dickinson
$227.15 /

+3.3 (+1.47%)

BDX Becton Dickinson
$227.15 /

+3.3 (+1.47%)

08/27/20 Goldman Sachs
Abbott test's sensitivity, low price 'positive surprises,' says Goldman Sachs
08/27/20 Wells Fargo
Abbott not focused on bringing Covid-19 test to home, says Wells Fargo
08/27/20 Morgan Stanley
Abbott 'may change the game' in COVID testing with BinaxNOW, says Morgan Stanley
08/07/20 Raymond James
Becton Dickinson price target raised to $285 from $265 at Raymond James
BDX Becton Dickinson
$227.15 /

+3.3 (+1.47%)

  • 21
    May
BDX Becton Dickinson
$227.15 /

+3.3 (+1.47%)

BDX Becton Dickinson
$227.15 /

+3.3 (+1.47%)

Recommendations
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink » 09:13
09/23/20
09/23
09:13
09/23/20
09:13
RGNX

Regenxbio

/

+

, NVS

Novartis

$88.87 /

-0.65 (-0.73%)

, IONS

Ionis Pharmaceuticals

$50.74 /

+0.53 (+1.06%)

, BIIB

Biogen

$272.65 /

+4.34 (+1.62%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PTCT

PTC Therapeutics

$46.12 /

+0.64 (+1.41%)

SVB Leerink notes that…

SVB Leerink notes that Regenxbio (RGNX) partner Novartis (NVS) indicated that the FDA has requested a confirmatory pivotal study for the regulatory submission of intrathecal Zolgensma in Spinal Muscular Atrophy. The firm estimates that this additional pivotal study, intended to supplement data from the STRONG study, will cause a 2-year delay to launch of intrathecal Zolgensma from previous estimates of approval in early 2022. The confirmatory trial requirement is unrelated to the partial clinical hold, which remains in place and could delay the confirmatory study initiation and enrollment, potentially pushing the launch out further. SVB Leerink believes these developments are a meaningful positive for Ionis Pharmaceuticals (IONS)/Biogen (BIIB) Spinraza and Roche (RHHBY)/PTC Therapeutics' (PTCT) risdiplam as they limit competition in older SMA patients to these two agents, and a painful negative for Regenxbio, with limited years of life remaining in the patents underlying the royalty stream on Zolgensma. The firm expects Ionis shares to trade up in relief and Regenxbio shares to be down sharply.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
/

+

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

RGNX Regenxbio
/

+

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/25/20 BofA
Regenxbio reinstated with a Buy at BofA
05/12/20 RBC Capital
Regenxbio initiated with a Sector Perform at RBC Capital
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
NVS Novartis
$88.87 /

-0.65 (-0.73%)

09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
09/10/20 UBS
Novartis upgraded to Buy from Neutral at UBS
09/01/20 Morgan Stanley
Novartis upgraded to Overweight from Equal Weight at Morgan Stanley
08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

09/22/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target raised to $59 from $56 at Cantor Fitzgerald
09/14/20 JPMorgan
Ionis Pharmaceuticals resumed with a Neutral at JPMorgan
09/08/20 Citi
Ionis Pharmaceuticals price target lowered to $74 from $78 at Citi
09/02/20 Benchmark
Benchmark starts Ionis at Hold, cautious on Spinraza competition
BIIB Biogen
$272.65 /

+4.34 (+1.62%)

09/18/20 RBC Capital
Biogen price target lowered to $277 from $284 at RBC Capital
09/17/20 Morgan Stanley
Court ruling eliminates hurdle for Tecfidera generics, says Morgan Stanley
09/16/20 Raymond James
Mylan exclusivity on Tecfidera generic abruptly ending, says Raymond James
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

08/24/20 Raymond James
PTC Therapeutics initiated with an Outperform at Raymond James
08/11/20 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $85 at Cantor Fitzgerald
07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
/

+

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

Hot Stocks
Baxter gets FDA approval of new formulations of Clinimix Injections » 08:05
09/23/20
09/23
08:05
09/23/20
08:05
BAX

Baxter

$79.02 /

-1.21 (-1.51%)

Baxter International…

Baxter International announced the U.S. Food and Drug Administration, FDA, approval of new formulations of Clinimix Injections and Clinimix E Injections. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.,2 making it easier to reach patient protein targets while delivering less fluid and dextrose than provided by existing formulations. Parenteral nutrition is an intravenous administration of nutrition that plays an important role in helping reduce malnutrition and may include proteins, carbohydrates, lipids , electrolytes, vitamins and other trace elements. Guidelines from the Society of Critical Care Medicine, SCCM, and the American Society for Parenteral and Enteral Nutrition, ASPEN, recommend between 1.2 and 2.0 grams of protein per kilogram of body weight per day for a critically ill adult patient, and note that many patients may benefit from protein supplementation.5 These patients may also have other nutritional considerations, like controlling blood glucose levels4 and, in many cases, restricting fluid intake. "The introduction of Clinimix and Clinimix E formulations offers the highest protein in a multi-chamber bag in the U.S., allowing clinicians more flexibility in meeting their patients' nutritional goals," said Heather Knight, general manager of Baxter's U.S. hospital products business. "Clinimix and Clinimix E with Higher Protein complement Baxter's diverse portfolio of formulations that focus on helping improve care for critically ill patients."

ShowHide Related Items >><<
BAX Baxter
$79.02 /

-1.21 (-1.51%)

BAX Baxter
$79.02 /

-1.21 (-1.51%)

09/04/20
Fly Intel: Top five analyst downgrades
09/04/20 Argus
Baxter downgraded to Hold from Buy at Argus
09/04/20 Argus
Baxter downgraded to Hold from Buy at Argus
08/31/20 Piper Sandler
Piper Sandler reiterates Overweight on Baxter following Theranova approval
BAX Baxter
$79.02 /

-1.21 (-1.51%)

BAX Baxter
$79.02 /

-1.21 (-1.51%)

Recommendations
Blueprint Medicines price target raised to $113 from $105 at BMO Capital » 07:45
09/23/20
09/23
07:45
09/23/20
07:45
BPMC

Blueprint Medicines

$87.34 /

+10.1 (+13.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

BMO Capital analyst…

BMO Capital analyst George Farmer raised the firm's price target on Blueprint Medicines (BPMC) to $113 from $105 and keeps an Outperform rating on the shares after its top-line data from EXPLORER and PATHFINDER trials. The analyst notes that avapritinib looks like a "winner" in advanced systemic mastocytosis, or aSM. Farmer also cites Blueprint's "tremendous year", getting approval for avaprintib in PDGFRa GIST as well as securing a "big" partnership with Roche (RHHBY).

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

09/23/20 Barclays
Blueprint Medicines price target raised to $90 from $77 at Barclays
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
07/15/20 Deutsche Bank
Blueprint Medicines price target raised to $95 from $85 at Deutsche Bank
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
08/18/20 Morgan Stanley
Roche price target raised to CHF 372 from CHF 370 at Morgan Stanley
RHHBY Roche
$0.00 /

+ (+0.00%)

BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

  • 23
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.